[遗传性凝血因子XI缺乏症患者的家庭研究和输血]
Ya-Xin Han1, Ying Ren1, Rong Zhao1
1Department of Blood Transfusion, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
Zhongguo shi yan xue ye xue za zhi
|September 11, 2025
概括
一个家族的遗传性凝血因子XI (FXI) 缺乏与F11基因中的复合异合体变体有关. 一个量身定制的新鲜冷血输血方案可以防止手术期间出血.
科学领域:
- 遗传学 遗传学是一种遗传学.
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 遗传性凝血因子XI (FXI) 缺乏症是一种罕见的出血障碍.
- 确定遗传基础对于诊断和管理至关重要.
研究的目的:
- 调查一家遗传性FXI缺乏症的家庭.
- 确定遗传病因,并分析出血风险.
- 建立一个有效的输血方案.
主要方法:
- 从家庭成员收集血液样本进行凝血测试.
- 进行了全外因子测序和桑格测序,以识别F11基因变异.
- 利用生物信息学和ACMG指南来评估变体的病原性.
- 采用血栓显微镜 (TEG) 来评估凝血功能和输血疗效.
主要成果:
- 试验者表现出显著延长的APTT和极低的FXI活性/抗原.
- 已识别的复合异构F11变种:c.738G>A (p.Trp246*) (致病性) 和c.1288G>A (p.Ala430Thr) (可能致病性).
- 以TEG为指导的新鲜冷血 (FFP) 输血方案预防了手术出血.
结论:
- 复合异合体F11变种是该家族遗传性FXI缺乏症的原因.
- 准确的基因诊断和TEG引导的输血协议至关重要.
- 有效的管理策略可以减轻出血风险.
相关概念视频
Blood Transfusion and Agglutination
14.0K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
14.0K
Blood Transfusion
2.1K
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
2.1K
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K


